The weakest employment recovery in seven decades is proving a boon to equity markets.
Five years into a rally that has restored $14 trillion to share prices, U.S. payrolls remain 1.5 million below the level in 2008, according to data compiled by Bloomberg. Resistance to hiring from ConocoPhillips (COP) to Walt Disney Co. (DIS) will help push Standard & Poor’s 500 Index profit margins above 10 percent next year, the highest ever, data show. Below-average employment was cited last month by Federal Reserve chairman nominee Janet Yellen as the biggest obstacle to raising interest rates.
While American workers struggle, investors are benefiting as expense reductions and record low borrowing costs drive profits and underpin a 167 percent advance in the S&P 500 over the past 57 months. To bulls like Michael Holland at Holland & Co., equities will keep rallying as long as the Fed remains more concerned about employment than inflation.
“The w eakness in jobs is continuing fodder for the Fed to fulfill its most recent and steadfast comments about the support of the economy,” Holland, who oversees more than $4 billion in New York, said in a Nov. 26 phone interview. “Until the labor market gets better, the two parts of dual mandate have to be served,” he said. “I’m still pretty set in my position and prepared to see the market go higher.”
Top Gas Utility Stocks To Watch For 2015: Permian Basin Royalty Trust (PBT)
Permian Basin Royalty Trust (the Trust), incorporated in 1980, is an express trust. The Trust’s principal assets are net overriding royalties conveyed to the Trust, including a 75% net overriding royalty carved out of Southland Royalty’s fee mineral interests in the Waddell Ranch in Crane County, Texas (the Waddell Ranch properties), and a 95% net overriding royalty carved out of Southland Royalty’s major producing royalty interests in Texas (the Texas Royalty properties). Bank of America, N.A. is the Trustee for the Trust.
Waddell Ranch Properties
The mineral interests in the Waddell Ranch, from which such net royalty interests are carved, vary from 37.5% (Trust net interest) to 50% (Trust net interest) in 78,715 gross (34,205 net) producing acres. A majority of the proved reserves are attributable to six fields: Dune, Sand Hills (Judkins), Sand Hills (McKnight), Sand Hills (Tubb), University-Waddell (Devonian) and Waddell. At December 31, 20 12, the Waddell Ranch properties contained 889 gross (400 net) productive oil wells, 64 gross (30 net) productive gas wells and 177 gross (506 net) injection wells.
Burlington Oil & Gas Company LP (BROG) is the operator of the Waddell Ranch properties. As of December 31, 2012, six major fields on the Waddell Ranch properties account for more than 80% of the total production. In the six fields, there are 12 producing zones ranging in depth from 2,800 to 10,600 feet. Most prolific of these zones are the Grayburg and San Andres, which produce from depths between 2,800 and 3,400 feet. Also productive from the San Andres are the Sand Hills (Judkins) gas field and the Sand Hills (McKnight) oil field, the Dune (Grayburg/San Andres) oil field, and the Waddell (Grayburg/San Andres) oil field.
The Dune and Waddell oil fields are productive from both the Grayburg and San Andres formations. The Sand Hills (Tubb) oil fields produce from the Tubb formation at d epths averaging 4,300 feet, and the University Waddell (Devo! nian) oil field is productive from the Devonian formation between 8,400 and 9,200 feet. The Waddell Ranch properties are producing properties, and all of the major oil fields are being waterflooded for the purpose of facilitating enhanced recovery. As of December 31, 2012, there were no drill wells and 13 workovers in progress on the Waddell Ranch properties.
Texas Royalty Properties
The Texas Royalty properties consist of royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole and others located in 33 counties across Texas. The Texas Royalty properties consist of approximately 125 separate royalty interests containing approximately 303,000 gross (approximately 51,000 net) producing acres.
- [By Lawrence Meyers]
Permian Basin Royalty Trust (PBT) is a royalty trust, meaning it pools together royalty rights for various energy-producing properties. I prefer trusts that are widely diversified. In this case, Permian holds a 75% net overriding royalty interest in six properties in Crane County, Texas; and a 95% net overriding royalty interest in fields spread across 33 other counties in Texas. In total, we’re talking 400 oil wells, 30 gas wells, and 500 injection wells. That’s plenty diversified. Yeehaw for its 8.3% yield!
- [By Rick Munarriz]
Permian Basin Royalty Trust (NYSE: PBT ) is also flowing more freely with its distributions. The trust’s new rate of $0.088488 per unit may seem to be a numerical stretch, but it’s a healthy 45% pop from its prior monthly payout. Increased oil production and higher oil prices helped the company generate more money that it passes on to its investors.
Top Gas Utility Stocks To Watch For 2015: Clovis Oncology Inc (CLVS)
Clovis Oncology, Inc. (Clovis) incorporated on April 20, 2009, is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations. During the year ended December 31, 2010, the Company was in the process of developing three product candidates for which it holds global marketing rights: CO-101, a lipid-conjugated form of the anti-cancer drug gemcitabine; CO-1686, an oral epidermal growth factor receptor (EGFR) mutant-selective inhibitor and CO-338, a poly ADP (Adenosine Diphosphate)-ribose polymerase (PARP) inhibitor. Effective November 19, 2013, Clovis Oncology Inc acquired the entire share capital of Ethical Oncology Science SpA.
CO-101 – a Lipid-Conjugated Form of the Anti-Cancer Drug Gemcitabine
CO-101 is designed to treat patients with pancreatic cancer whose tumors express low amounts of a membrane transporter protein on the surface of the cancer cell known as hENT1 and are thus expected to be resistant to standard gemcitabine-based therapy. Based on the published results of multiple studies assessing the correlation of hENT1 expression to survival outcomes in pancreatic cancer patients treated with gemcitabine, the Company estimates that approximately 40% to 50% of pancreatic patients express low levels of hENT1, and thus derive little or no benefit from gemcitabine therapy. CO-101 is in an international, randomized and controlled 360-patient study for the first-line treatment of metastatic pancreatic cancer. This open-label study compares CO-101 to gemcitabine as a first-line therapy in patients with metastatic pancreatic cancer. Clovis is partnered with Ventana Medical Systems for the development and commercialization of a companion diagnostic for the assessment of hENT1 levels.
CO-1686-an Oral EGFR Mutant-Selective ! Inhibitor
CO-1686 is an orally available, small molecule covalent inhibitor of the cancer-causing mutant forms of EGFR for the treatment of non-small cell lung cancer (NSCLC). CO-1686 targets both the initial activating EGFR mutations as well as the primary resistance mutation, T790M, it treats both first- and second-line NSCLC patients with EGFR mutations. Such initiating activating mutations occur in approximately 10% to 15% of NSCLC cases in Caucasian patients and approximately 30% to 35% of NSCLC cases in East Asian patients. Following treatment with approved NSCLC therapies, Tarceva (erlotinib) or Iressa (gefitinib), both known as tyrosine kinase inhibitors (TKIs), approximately half of these patients develop the T790M mutation.
The Company focuses on the development of CO-1686 as both a second-line therapy for EGFR-mutated NSCLC patients who become resistant to TKIs due to the emergence of the T790M secondary mutation and as a first-line trea tment for EGFR-mutated NSCLC. Clovis is partnered with Roche Molecular Systems for the development and commercialization of a companion diagnostic for identification of EGFR mutations.
CO-338-a PARP Inhibitor
CO-338 is a small molecule PARP inhibitor that the Company focuses to develop as both monotherapy and in combination with chemotherapeutic agents for the treatment of selected cancer patients. CO-338 is in a Phase I clinical trial to determine the maximum tolerated dose of oral CO-338 that can be combined with intravenous, or IV, platinum chemotherapy in the treatment of solid tumors. This program is supplemented by two ongoing investigator-initiated trials, using the IV formulation of CO-338: a Phase I/II study in germ-line BRCA mutant breast and ovarian cancer and a Phase II study in the adjuvant treatment of germ-line BRCA mutant and triple-negative breast cancer. The Company also focuses on initiating a Phase I monotherapy study of the oral formulation, to determine an appropriate dose and schedule.!
The Company competes with Eli Lilly, Teva Pharmaceutical Industries, APP Pharmaceuticals, AB Science SA, Amgen Inc., Astellas Pharma, BioSante Pharmaceuticals, Inc., Celgene Corporation, Immunomedics, Inc., Lorus Therapeutics, Threshold Pharmaceuticals, Inc., Boehringer Ingelheim, Pfizer, Sanofi-Aventis, Astra Zeneca, Abbott, Merck, Eisai, Cephalon and Biomarin.
- [By John Kell and Lauren Pollock var popups = dojo.query(“.socialByline .popC”); ]
Clovis Oncology(CLVS) posted positive findings from a study of a lung-cancer treatment. The Phase 1 study of the oral treatment, called CO-1686, demonstrated “encouraging” results and progression-free survival in patients, Clovis said. Shares increased 4.2% to $80.75 in recent premarket trading.
- [By Jake L’Ecuyer]
Clovis Oncology (NASDAQ: CLVS) was also up, gaining 7.26 percent to $79.35 after the company announced 2014 objectives and financial outlook. The company projected to initiate three global registration studies for CO-1686.
- [By John Udovich]
On Wednesday, small cap cancer stock Clovis Oncology Inc (NASDAQ: CLVS) soared 16.68% after announcing a $200 million cancer deal plus the biotech has more than tripled since late 2011, meaning it might be time to take a closer look at what’s driving the stock higher as well as look at the performance of biotech ETF benchmarks like iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) and SPDR S&P Biotech ETF (NYSEARCA: XBI).
- [By John Udovich]
Bubble talk, biotech IPO setbacks plus news about small cap biotechs like Intrexon Corp (NYSE: XON) and TNI BioTech (OTCMKTS: TNIB) have dominated biotech news this week or in recent weeks. Just consider the following news:
Why There is No Biotech Bubble & Where to Look for Value in Biotech. Marshall Gordon, the Director and senior health-care analyst of ClearBridge Investments, was recently interviewed by Barron’s where he stated his belief that there is no biotech bubble because biotech stocks have delivered new drugs and have shown an ability to innovate. With that said, he added that the sector got ahead of itself while some biotechs suffered setbacks plus hedge funds decided to trim risk from their portfolios. Nevertheless, Marshall likes or is watching mid cap biotechs BioMarin Pharmaceutical Inc (NASDAQ: BMRN) and Pharmacyclics, Inc (NASDAQ: PCYC) along with small cap biotechs Pacira Pharmaceuticals Inc (NASDAQ: PCRX) and Clovis Oncology Inc (NASDAQ: CLVS). He also added that recent biotech IPOs have been lesser quality names than earlier offerings. A Trio of Biotech IPO Setbacks. FierceBiotech has summarized how a trio of biotech IPO have suffered setbacks. Specifically, Relypsa (NASDAQ: RLYP), a late-stage biotech developing a treatment for hyperkalemia, slashed its asking price on 6.9 million shares to $12 a share to raise $82 million from a range of $16 to $19 a share while Xencor (NASDAQ: XNCR), a biotech developing antibodies for severe autoimmune/allergic diseases and cancer, has dropped its IPO price to $7 a share to raise $75 million from a range of $14 to $16. Meanwhile, Celladon, which is developing a first-in-class gene therapy for patients with systolic heart failure, has postponed its IPO citing poor market conditions. Coming Biotech IPOs. Nevertheless, FierceBiotech has noted that GeNO Healthcare (NASDAQ: GNO) is looking to raise $50 million for its new, patient-friendly approach for delivering inhaled nitric oxide on the
Top Gas Utility Stocks To Watch For 2015: Fluidigm Corporation(FLDM)
Fluidigm Corporation engages in the development, manufacture, and marketing of microfluidic systems for growth markets in the life science and agricultural biotechnology (Ag-Bio) industries. The company?s proprietary microfluidic systems consist of instruments and consumables, including chips (integrated fluidic circuits) and reagents. Its technology enables customers to perform and measure various biochemical reactions on samples smaller than the content of a single cell by utilizing minute volumes of reagents and samples; and rapid preparation of multiple samples in parallel for next generation DNA sequencing. The company?s products include the BioMark HD system, which performs high-throughput gene expression analysis using real-time and end point PCR, SNP genotyping, single-cell analysis, and digital PCR using TaqMan, EvaGreen dye, and other chemistries; The EP1 System that performs end point PCR and is commonly used in production settings for Ag-Bio, digital PCR, and c opy number variation experiments using TaqMan, EvaGreen dye, and other chemistries; and the Access Array system that enables automated sample preparation and tagging for next generation DNA sequencers. The company serves pharmaceutical and biotechnology companies, academic institutions, diagnostic laboratories, and Ag-Bio companies. Fluidigm Corporation distributes its instruments and supplies through direct field sales and support organizations in North America, Europe, and Japan; and through distributors or sales agents in parts of Europe, Latin America, the Middle East, and the Asia-Pacific region. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.
- [By John Kell]
Bio-technology company Fluidigm Corp.(FLDM) agreed to acquire DVS Sciences Inc. for about $208 million to expand its portfolio of single-cell technology products. DVS manufactures and distributes bioanalytical products for biological research and future clinical applications. Shares dropped 2.3% to $40.02 premarket.
- [By Sean Williams]
What: Shares of Fluidigm (NASDAQ: FLDM ) , a manufacturer of microfluidic systems for the biotech, pharmaceutical, and academic research sectors, shot higher by as much as 14% after reporting its first-quarter-earnings results.
- [By Seth Jayson]
Fluidigm (Nasdaq: FLDM ) reported earnings on May 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), Fluidigm beat slightly on revenues and exceeded expectations on earnings per share.
- [By Seth Jayson]
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven’t materialized. Is the current inventory situation at Fluidigm (Nasdaq: FLDM ) out of line? To figure that out, start by comparing the company’s inventory growth to sales growth. How is Fluidigm doing by this quick checkup? At first glance, pretty well. Trailing-12-month revenue increased 24.0%, and inventory increased 14.4%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue expanded 32.8%, and inventory increased 14.4%. Over the sequential quarterly period, the trend looks worrisome. Revenue dropped 7.2%, and inventory grew 2.8%.
Top Gas Utility Stocks To Watch For 2015: Nuvilex Inc (NVLX.PK)
Nuvilex, Inc., incorporated on October 28, 1996, operates independently and through wholly owned subsidiaries. The Company is a biotechnology and life technology company with a specialty in living-cell encapsulation. It is focused on preparations for a new pancreatic cancer clinical trial through live-cell encapsulation of chemotherapeutic-converting cells. It has created the hardware and operating platform to envelop or encapsulate its own or other company’s software products, or cells. These cells are then packaged in its live cell encapsulation operating system. Its products include Cinnechol, Cinnergen, Cinnsational, Citroxin, Cyclosurface, Cosmetics, Infinitink, Talsyn, Oraphyte and PurEffect. On July 10, 2013, the Company acquired Bio Blue Bird AG. In November 2013, the Company announced that it has acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes from SG Austria Pt e. Ltd.
Cinnechol is a gluten free/wheat free all-natural supplement designed to help maintain normal cholesterol levels and support normal cardiovascular function through a healthy diet and regular exercise and to help individuals manage cardiovascular and metabolic disorders. Cinnechol may provide a natural alternative for those with high cholesterol and intolerant of, or elect not to take statins.
Cinnergen is a gluten free/wheat free all-natural liquid whole food nutritional supplement that provides nutrients to help the body efficiently process glucose, is made from natural ingredients. Clinical studies using Cinnergen, as well as peer reviewed research suggest constituents of Cinnergen may help to reduce glucose absorption in the small intestine, limit glucose synthesis and increase its metabolism and prevent conditions associated with pre-diabetes or diabetes types one and two by delivering ami n o acids, vitamins, minerals, enzymes, antioxidants, and pl! an! t based extracts to the body thus helping control glucose levels.
Cinnsational is a gluten free/wheat free all-natural calorie-free, liquid nutritional supplement contains concentrated blend vitamins, essential amino acids, and other beneficial ingredients to help the body combat symptoms associated with alcohol sensitivity, including nausea, fatigue and headaches.
Citroxin is an all-natural, eco-friendly surface cleaner. Citroxin is protected by patents in the United States and Thailand.
Nuvilex’s Cyclosurface color enhancement technology provides formulators and manufacturers of cosmetics and other consumer products the ability to use less wax and other potentially detrimental additives in their products through a lipophilic surface treatment. It improves pigment dispersion enabling products that feel lighter on the skin and make the skin look r adia nt while maintaining or enhancing the color and durability of the cosmetic product.
I-Boost Immune Bar
I-Boost Immune Bar is a gluten free/wheat free all-natural nutritional bar designed to protect, stimulate, and boost the immune system. It was reformulated and contains a blend of vitamins, minerals, and other ingredients designed to enhance the body’s natural ability to defend itself.
Infinitink is a permanent, yet removable tattoo ink, was engineered specifically for removal in fewer laser treatments than standard tattoo ink. Typically, lasers used for removal of tattoos use 532 and 1064 nanometer wavelengths which closely match the Infinitink tattoo pigments, enabling more easily removed tattoos.
Oraphyte is the Company’s all-natural nematocide, is a non-toxic, biodegradable formulation that damages a nematode’s skin surface, compromising its immune system, enabling it to be killed by the environment. In field tests, Oraphyte! redu! ce! d probl! ematic nematodes, parasitic plant worms found in soil, compared to non-treated controls.
PurEffect is a three part, all-in-one acne treatment designed to cleanse, tone, and heal skin combining ingredients to help maintain a radiant, blemish-free complexion. Benzoyl peroxide, the active ingredient in purEffect is the safest, recommended ingredient used to treat acne. This line of products completed pre-marketing testing by CK41.
Specialty, Private Label Inks
The Company has the potential to manufacture specialty inks for private label customers derived from the Company’s Virgin and Infinitink product lines and are formulated to specific customer needs. The Company’s specialty inks are formulated to be all natural, heavy metal and toxin-free.
Talsyn Scar Cream
Talsyn Scar Cream is a cream that delivers lipids, peptides, and botanical extracts to the skin. It was clinically proven to impro ve appearance of keloids, surgical incisions, and scars through decreasing their width, length, depth, and redness for both old and new scars. Talsyn Scar Cream has been endorsed and used by plastic and reconstructive surgeons.
- [By Alan Brochstein]
I actually spoke with Mr. Tim Matula, who is a former director and also handled investor relations for Diamond Ranch Foods (the predecessor company). Mr. Matula is also a long-time director at Nuvilex (NVLX.PK), which I recently suggested is an overly promoted stock exhibiting several of the signs about which FINRA has been warning investors (more on this later). Matula answered the phone number included on recent press releases by PLPL – I was expecting to hear an answering machine, as my call was in the late evening. He explained that he was no longer involved with the company due to having too many time-constraints. He also explained his sale of 4.9mm shares back to the company at $0.025 on February 7th, suggesting an open market sale would have been impossible. Note that PLPL has never traded below $0.04, so I found this curious. It was Matula who passed me along to Shane Traveller. He also told me that he is the brother of Tom Matula, the Chairman of the Scientific Ad visory Board (more later).
Top Gas Utility Stocks To Watch For 2015: Ulta Salon Cosmetics and Fragrance Inc (ULTA)
Ulta Salon, Cosmetics & Fragrance, Inc. (Ulta), incorporated on January 9, 1990, is a beauty retailer, which provides one-stop shopping for prestige, mass and salon products and salon services in the United States. During the year ended January 28, 2012 (fiscal 2011), the Company opened 61 new stores. It operates full-service salons in all of its stores. Its Ulta store format includes an open and modern salon area with approximately eight to 10 stations. The entire salon area is approximately 950 square feet with a concierge desk, skin treatment room, semi-private shampoo and hair color processing areas. Each salon is a full-service salon offering hair cuts, hair coloring and permanent texture, with salons also providing facials and waxing.
The Company offers products in the categories, such as cosmetics, which includes products for the face, eyes, cheeks, lips and nails; haircare, which includes shampoos, conditioners, styling products, and hair accessories; salon styling tools, which includes hair dryers, curling irons and flat irons; skincare and bath and body, which includes products for the face, hands and body; fragrance for both men and women; private label, consisting of Ulta branded cosmetics, skincare, bath and body products and haircare, and other, including candles, home fragrance products and other miscellaneous health and beauty products. The Company has combined its three operating segments: retail stores, salon services and e-commerce, into one reportable segment.
The Company competes with Macy’s, Nordstrom, Sephora, Bath & Body Works, CVS/pharmacy, Walgreens, Target, Wal-Mart, Regis Corp., Sally Beauty and JCPenney salons.
- [By Rich Bieglmeier]
[Related -Ulta Salon, Cosmetics & Fragrance, Inc. (ULTA): Bullish Options Play Eyes Further Upside in Ulta]
Ulta operates specialty retail stores in the United States. Its stores offer cosmetics, fragrance, haircare, and skincare products, as well as related accessories and services. As of February 1, 2014, the company operated 675 retail stores across 46 states. It also operates full services salons in its stores and distributes its products through operating ulta.com.
- [By Jake L’Ecuyer]
Equities Trading UP
Ulta Salon, Cosmetics & Fragrance (NASDAQ: ULTA) shares shot up 7.31 percent to $96.05 after the company reported better-than-expected fourth-quarter earnings. Ulta Salon posted its quarterly earnings of $1.09 per share, beating analysts’ estimates of $1.07 per share.
- [By DailyFinance Staff]
Stocks bounced in and out of the plus column before picking a direction on Friday. Unfortunately, the path chosen was down again, though not far. The Dow Jones industrial average (^DJI) extended its losing streak to five days, dropping another 43 points. The Standard & Poor’s 500 (^GSPC) fell 5 and the Nasdaq composite (^IXIC) lost 15 points. In all, each of the major averages lost in the neighborhood of a quarter of a percent Friday, and all lost ground for the week. Meanwhile, another once-popular teen retailer took a tumble. Shares of Aeropostale (ARO) tumbled 20 percent after the retailer posted a wider than expected quarterly loss. The stock is now down 60 percent over the past year. But investors were buying some other retailers. Zumiez (ZUMZ), also geared toward teens, rose 2½ percent despite forecasting a loss in the current quarter. A couple of chains geared toward women did well. Ulta Salon (ULTA) gained nearly 6½ percent as earnings topped expectations. Ann (ANN), best known for its Ann Taylor stores, rose 7½ percent. And Coach (COH) gained 2 percent. Other gainers today: Green Mountain (GMCR), maker of Keurig, was up 7 percent, after expanding its deal with Starbucks. Liberty Media (LSTZA) ended its deal to buy those shares of Sirius XM (SIRI) it doesn’t already own. Both stocks gained on the news; Liberty up 7 percent, Sirius up 2 percent. And Castlight Health (CSLT) soared nearly 150 percent above its $16 a share IPO price. The company, which helps workers choose healthcare benefits, stands to gain from Obamacare. On the downside: Tesla (TSLA) lost another 3 percent on reports that New York could become the fifth state to block the company from selling direct to consumers. Still, Tesla has a pretty good track record. It’s stock has soared more than 500 percent over the past year. Biotechs continued to lose ground. Celgene (CELG) fell 4 percent on a double dose of bad news. British regulators reportedly plan to rejec
- [By John Kell and Lauren Pollock var popups = dojo.query(“.socialByline .popC”); ]
Ulta Salon Cosmetics & Fragrance Inc.(ULTA) said its fiscal fourth-quarter earnings rose 9.5% on the beauty-products retailer’s better-than-expected sales growth. Shares climbed 7.6% to $96.35 premarket.
Top Gas Utility Stocks To Watch For 2015: Mast Therapeutics Inc (MSTX)
Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., incorporated in December 1995, is a development-stage company biopharmaceutical company focused on developing product candidates. The Company’s product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. As of December 31, 2011, the Company also is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel. The Company offers ANX-188 (purified poloxamer 188), ANX-514 (docetaxel for injectable emulsion) and Exelbine (vinorelbine injectable emulsion). In April 2011, the Company acquired SynthRx, Inc. In February 2014, Mast Therapeutics Inc completed its acquisition of Aires Pharmaceuticals, Inc. Aires became a wholly-owned subsidiary of Mast Therapeutics.
ANX-188 (purified poloxamer 188)
ANX-188 is an aqueous solution of a purified form of poloxamer 188. Poloxamer 188 (P1880, is a nonionic, block copolymer that has been found to improve microvascular blood flow by reducing viscosity, particularly under low shear conditions, and by reducing adhesive frictional forces. The Company’s purified form of P188 (purified P188), which is the active ingredient in ANX-188, was designed to eliminate certain low molecular weight substances present in P188 (non-purified), which is primarily responsible for the moderate to moderately severe elevations in serum creatinine levels (acute renal dysfunction) observed in prior clinical studies of P188 (non-purified). Purified P188 has been evaluated in multiple clinical studies by a prior sponsor, including a 255-patient, phase III study.
ANX-514 (docetaxel for injectable emulsion)
ANX-514 is a detergent-free emulsion formulation of docetaxel, an intravenously-injected chemotherapy drug c ommonly used to treat solid tumors. Taxotere, a branded form! ulation of docetaxel, is approved to treat breast, non-small cell lung, prostate, gastric, and head and neck cancers. ANX-514 was designed to have clinically comparable release of docetaxel relative to Taxotere while eliminating the presence of polysorbate 80 and ethanol, both of which are used to solubilize docetaxel in the Taxotere formulation. The ANX-514 formulation solubilizes docetaxel using oil droplets consists of a combination of non-toxic excipients. Docetaxel is contained within these oil droplets and can be administered intravenously without using detergents as pharmaceutical vehicles. Once in central circulation, the emulsion is metabolized rapidly, leaving chemically-identical active ingredient to exert its cytotoxic effect. ANX-514 may reduce the incidence and severity of hypersensitivity reactions and delay the onset of fluid retention.
Exelbine (vinorelbine injectable emulsion)
Exelbine is an emulsion formulation of the chemother apy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the United States to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer.
In August 2011, the Company received a complete response letter from the Food and Drug Administration (FDA) stating that it could not approve the Exelbine Non Disclosure Agreement (NDA) in its present form and that the bioequivalence study would need to be repeated because the authenticity of the drug products used in the bioequivalence trial could not be verified in accordance with FDA standards. However, the Company elected to discontinue independent development of Exelbine and as of December 31, 2011, the Company was seeking a partner or outside investor for the program to complete the necessary bioequivalence study.
The Company compete s with GlaxoSmithKline, Provenge and Pfizer.
- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many…) planned biotech IPOs that have recently been announced publicly:
- [By Lauren Pollock]
Mast Therapeutics Inc.(MSTX) said the U.S. Food and Drug Administration gave orphan-drug designation to its MST-188 drug for the treatment of acute limb ischemia, providing a boost for the biopharmaceutical firm. Shares surged.
- [By James E. Brumley]
A little over a month ago, owning Mast Therapeutics, Inc. (NYSE: MSTX) was nothing but pure misery. Shares plunged from $0.63 to $0.43 in one day, when details of a dilutive public offering were unveiled. As is so often the case though, the market may have overshot with the selling effort that KO’s MSTX. Though putting more shares ‘out there’ mathematically meant existing shareholders would have to share more of the company’s upside with newcomers, what’s slowly coming to light is that the inflow of new cash is still more advantageous to those prior shareholders; the company would progress little without it.
Top Gas Utility Stocks To Watch For 2015: Epizyme Inc (EPZM)
Epizyme, Inc., incorporated on November 1, 2007, is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers. The Company systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of its product candidates is directed towards patients with a particular genetically defined cancer.The Company is conducting a Phase I clinical trial of its advanced product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT, for the treatment of mixed lineage leukemia (MLL-r). The Company has identified its two lead product candidates using its product platform.
EPZ-5676 is an intravenously administered small molecu le inhibitor of DOT1L. The Company is developing EPZ-5676 for the treatment of MLL-r, an aggressive subtype of the two most common forms of acute leukemia, ALL and AML. Patients with MLL-r are routinely diagnosed with existing technologies that are commonly used in clinical setting. The Company’s Phase 1 clinical trial of EPZ-5676 is an open label, multicenter trial that has two phases.
The Company is developing EPZ-6438 as an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients who have an oncogenic point mutation in EZH2. EZH2 is an HMT that can become oncogenic and cause non-Hodgkin lymphoma and a range of other solid tumors. Two types of non-Hodgkin lymphoma, diffuse large B-cell lymphoma of germinal-center origin, or DLBCL, and follicular lymphoma, or FL, are particularly associated with an EZH2 point mutation. There are no therapies approved specifically for the treatmen t of cancer associated with an EZH2 point mutation.
- [By John Udovich]
Follow-on Stock Offerings From Small Cap Biotech Stocks. Thanks to the boom in biotech IPOs along with the sector’s overall performance, already listed biotechs have the option to ask investors for more cash in the form of a follow-on offering. Recently, FierceBiotech.com noted how four small cap biotechs raised $276 million from follow-on offerings in just one day last week. These small caps included Epizyme Inc (NASDAQ: EPZM) which raised $88 million, Halozyme Therapeutics, Inc (NASDAQ: HALO) which raised $100 million, Agenus Inc (NASDAQ: AGEN) which raised $52 million and Idera Pharmaceuticals Inc (NASDAQ: IDRA) which raised $36 million. FierceBiotech.com noted that the steady flow of about $4.5 billion a year in venture cash along with more than $3.5 billion from IPOs last year plus all of the follow-ons are helping to foster both company growth and accelerate drug development programs. Mixed Bag for Biotech IPOs. Last Wednesday also saw two small cap biotech IPOs fizzle in one day with small cap T cell vaccine developer Genocea Biosciences Inc (NASDAQ: GNCA) raising $60 million but then ending the day down 8.3% to close at $11 while Dutch drug developer uniQure NV (QURE) raised $81.9 million but fell more than 14% to $14.61. However, orphan drug stock Auspex Pharmaceuticals Inc (NASDAQ: ASPX), which is developing drugs to treat orphan diseases like Tourette syndrome, saw a 30.5% gain to close at $15.66 and raise $84 million. The Boston Globe quoted Michael Ringel, a partner and managing director at Boston Consulting Group who focuses on health care business, as saying:
“The mood is incredibly positive. Capital is flowing. [The biotech IPOs]… have been burning hot. I think it’s too early to suggest that is changing. I can’t predict the overall economy any better than anyone else, but I would expect a pretty good year for IPOs.”
- [By John Udovich]
It’s a new year and the first one and a half trading weeks of 2014 has not disappointed biotech investors as the sector and mid cap or small cap biotech or pharma stocks like Intercept Pharmaceuticals Inc (NASDAQ: ICPT), Epizyme Inc (NASDAQ: EPZM), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and TNI BioTech Inc (OTCQB: TNIB) either surging or producing some news plus there have been IPO filings for future listings for Flexion Therapeutics (NASDAQ: FLXN), Aldexa Therapeutics (NASDAQ: ALDX), Retrophin (NASDAQ: RTRX) and Dicerna Pharmaceuticals (NASDAQ: DRNA). Consider the following news so far this year:
- [By John Udovich]
On Tuesday, small cap biopharmaceutical company Epizyme Inc (NASDAQ: EPZM) surged 75.56% after the company announced that its EPZ-5676, a DOT1L inhibitor for acute leukemias, had reached its proof-of-concept milestone, meaning its worth taking a closer look at the stock as well as look at the share performance of cancer stocks like large cap Celgene Corporation (NASDAQ: CELG) and small caps Dendreon Corporation (NASDAQ: DNDN) and Geron Corporation (NASDAQ: GERN).
- [By Jake L’Ecuyer]
Epizyme (NASDAQ: EPZM) shot up 54.63 percent to $31.70 after the company reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.
Top Gas Utility Stocks To Watch For 2015: Ferrellgas Partners L.P. (FGP)
Ferrellgas Partners, L.P. engages in the distribution and sale of propane, and related equipment and supplies primarily in the United States. It transports propane to propane distribution locations, tanks on customers premises, or to portable propane tanks delivered to retailers. The company conducts its portable tank exchange operations under the Blue Rhino brand name through a network of independent and partnership-owned distribution outlets. The companys propane is primarily used for space heating, water heating, cooking, outdoor cooking using gas grills, crop drying, irrigation, weed control, and other propane fueled appliances; as an engine fuel for power vehicles and forklifts; and as a heating or energy source in manufacturing and drying processes. It serves approximately 1 million residential, industrial/commercial, portable tank exchange, agricultural, wholesale, and other customers in 50 States, the District of Columbia, and Puerto Rico. As of July 31, 2012, it had 924 propane distribution locations. The company also engages in the wholesale marketing of propane appliances; sale of refined fuels; and provision of common carrier services. Ferrellgas Partners, L.P. was founded in 1939 and is headquartered in Overland Park, Kansas.
- [By Monica Gerson]
Ferrellgas Partners LP (NYSE: FGP) is expected to report its Q2 earnings at $0.85 per share on revenue of $722.07 million.
American Midstream Partners LP (NYSE: AMID) is estimated to post a Q4 loss at $0.30 per share on revenue of $89.74 million.
- [By Robert Rapier]
But because SPH is more involved in the retail end of propane instead of the production/logistical side, it has been significantly outperformed by NGL Energy Partners (NYSE: NGL) and Ferrellgas Partners (NYSE: FGP). In short, the latter two are the ways to play higher propane prices, whereas SPH will see much less benefit from higher-priced propane.
- [By Robert Rapier]
The four propane-focused MLPs are AmeriGas Partners (NYSE: APU), Suburban Propane Partners (NYSE: SPH), NGL Energy Partners (NYSE: NGL), and Ferrellgas Partners (NYSE: FGP).
- [By Dan Caplinger]
Ferrellgas Partners (NYSE: FGP ) will release its quarterly report on Friday, and shares of the propane distributor have jumped to two-year highs recently. Yet with a somewhat different exposure to the industry than rivals AmeriGas (NYSE: APU ) and Suburban Propane (NYSE: SPH ) , will Ferrellgas earnings be able to grow enough to make optimistic investors satisfied?
Top Gas Utility Stocks To Watch For 2015: TransAtlantic Petroleum Ltd (TAT)
TransAtlantic Petroleum Ltd. is an international oil and gas company engaged in the acquisition, exploration, development and production of crude oil and natural gas. The Company holds interests in developed and undeveloped oil and gas properties in Turkey, Bulgaria and Romania. As of March 1, 2012, it held approximately 5.4 million net onshore acres. As of March 1, 2012, it was producing an aggregate of approximately 2,638 net barrels of oil per day. As of March 1, 2012, it held interests in 57 onshore exploration licenses and nine onshore production leases covering a total of 5.3 million gross acres in Turkey. On February 18, 2011, the Company’s wholly owned subsidiary TransAtlantic Worldwide, Ltd. acquired Direct Petroleum Morocco, Inc. and Anschutz Morocco Corporation and its wholly owned subsidiary TransAtlantic Petroleum Cyprus Limited. On June 7, 2011, TransAtlantic Worldwide acquired Thrace Basin Natural Gas (Turkiye) Corporation. Advisors’ Opinion:
- [By CRWE]
TransAtlantic Petroleum Ltd. (Amex:TAT) reported that the Turkish Competition Authority has approved the Company’s sale of its oilfield services business to Dalea Partners, LP (“Dalea”, an affiliate of N. Malone Mitchell, 3rd, the Company’s Chairman and Chief Executive Officer).